• Explore /
  • Poster
  • / A phase II open-label study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune-checkpoint inhibitor: The BREAKPOINT trial.

A phase II open-label study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune-checkpoint inhibitor: The BREAKPOINT trial.

Abstract Poster

Authors

null

Elena Verzoni

Fondazione IRCCS Istituto Nazionale Tumori, Milano, Italy

Elena Verzoni , Alessandra Bearz , Ugo De Giorgi , Franco Nole , Camillo Porta , Raffaele Ratta , Melanie Claps , Filippo Pagani , Antonia Martinetti , Agata Cova , Licia Rivoltini , Filippo G. De Braud , Giuseppe Procopio

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT03463681

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr TPS685)

DOI

10.1200/JCO.2019.37.7_suppl.TPS685

Abstract #

TPS685

Poster Bd #

K16

Abstract Disclosures

Similar Posters

First Author: Lijun Wang

First Author: Giuseppe Procopio

First Author: Giuseppe Procopio

First Author: Toni K. Choueiri